A strategy for the selection of monovalent antibodies that span protein dimer interfaces

Received for publication, May 6, 2019, and in revised form, July 15, 2019 Published, Papers in Press, August 6, 2019, DOI 10.1074/jbc.RA119.009213

Jamie B. Spangler, Ignacio Moraga, Kevin M. Jude, Christina S. Savvides, and K. Christopher Garcia

From the Howard Hughes Medical Institute and the Departments of Molecular and Cellular Physiology, Structural Biology, and Biology, Stanford University School of Medicine, Stanford, California 94305 and the Departments of Biomedical Engineering and Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland 21218

Edited by Peter Cresswell

Ligand-induced dimerization is the predominant mechanism through which secreted proteins activate cell surface receptors to transmit essential biological signals. Cytokines are a large class of soluble proteins that dimerize transmembrane receptors into precise signaling topologies, but there is a need for alternative, engineerable ligand scaffolds that specifically recognize and stabilize these protein interactions. Recombinant antibodies can potentially serve as robust and versatile platforms for cytokine complex stabilization, and their specificity allows for tunable modulation of dimerization equilibrium. Here, we devised an evolutionary strategy to isolate monovalent antibody fragments that bridge together two different receptor subunits in a cytokine–receptor complex, precisely as the receptors are disposed in their natural signaling orientations. To do this, we screened a naive antibody library against a stabilized ligand–receptor ternary complex that acted as a "molecular cast" of the natural receptor dimer conformation. Our selections elicited “stapler” single-chain variable fragments (scFvs) of antibodies that specifically engage the interleukin-4 receptor heterodimer. The 3.1 Å resolution crystal structure of one such stapler revealed that, as intended, this scFv recognizes a composite epitope between the two receptors as they are positioned in the complex. Extending our approach, we evolved a stapler scFv that specifically binds to and stabilizes the interface between the interleukin-2 cytokine and one of its receptor subunits, leading to a 15-fold enhancement in interaction affinity. This demonstration that scFvs can be selected to recognize epitopes that span protein interfaces presents new opportunities to engineer structurally defined antibodies for a broad range of research and therapeutic applications.

Ligand-mediated receptor dimerization is the most prevalent signaling mechanism used by secreted proteins to activate their cognate cell surface receptors. In particular, transmembrane receptors of the cytokine and receptor tyrosine kinase families signal when oriented into specific receptor dimer geometries (1–3). Cytokines constitute a class of soluble ligands that act through dimeric membrane-embedded receptors to elicit a wide range of biological activities, particularly those pertinent to immune regulation (3–5). Cytokines bind to receptor extracellular domains (ECDs) and either reorient quiescent dimers or enforce dimerization of monomeric subunits (Fig. 1A, left) (6–11). Extracellular dimerization results in activation of Janus kinases (JAKs) constitutively associated with the receptor intracellular domains, which recruit and activate signal transducer and activator of transcription (STAT) proteins to effect transcriptional programs that determine cell fate (12–15).

There has been a great deal of interest in harnessing the agonistic potential of JAK/STAT cytokines as immunotherapeutics, but so far success has been very limited for several practical reasons (16, 17). First, the short in vivo half-life (typically <5 min) of cytokines mandates frequent injection or continuous infusion. Second, cytokines are pleiotropic, often activating a wide range of cell types expressing shared receptors, which hinders efficacy and can lead to systemic toxicity. Finally, these ligands are difficult to re-engineer or modify without concerns about immunogenicity (18–22). Thus, there exists a need for new modulators of protein dimerization that are based on protein scaffolds with both improved druglike properties and the capacity to serve as engineering substrates.

Monoclonal antibodies present stable, engineerable scaffolds that benefit from extended in vivo half-life due to interactions...
with neonatal Fc receptors (23, 24), and they can act as bivalent dimerization modulators for cytokine receptors. Previous work has demonstrated that certain cytokine receptor-targeted bivalent antibodies can activate signaling in the absence of cytokine (Fig. 1A, center) (25–31). However, these molecules enforce unnatural receptor dimer geometries, which can impact the nature of signal activation (Fig. 1A, center) (31). Antibodies that potentiate cytokine action by enhancing cytokine–receptor binding have also been reported (32, 33). Here, we sought to develop an evolutionary strategy for the discovery of antibody-based constructs that simultaneously engage two interacting subunits within dimerized receptors, as they are disposed in their native signaling conformations induced by endogenous cytokines (Fig. 1A, right).

Antibody Fab fragments or single-chain variable fragments (scFvs) are widely known to recognize “composite” ligand surfaces, such as Fabs that bind across the interfaces between different subunits of a multimeric antigen. Yet it is not clear whether such composite interface-recognition Fabs can be evolved to specifically recognize and bridge protein interfaces. We wished to isolate monovalent antibodies (which we term “staplers”) that bind to the composite dimer surface formed by the “stem region” of the receptors when complexed with their natural cytokine ligands (i.e. the “product complex”) (Fig. 1B). We used a soluble cytokine–receptor ECD complex to act as a “molecular cast” of the receptor dimer signaling conformation to isolate monovalent antibody fragments specific for the productive signaling complex, but not for the individual complex components. We hypothesized that the evolved antibodies would be specific for the “locked” receptor dimer stem region, binding to the receptor subunits in the geometry induced by the natural cytokine (Fig. 1A).

We focused our stapler engineering efforts on the interleukin-4 (IL-4) cytokine, a member of the family of common \(\gamma\) chain (\(\gamma_c\)) cytokines, which are critical for lymphocyte homeostasis and have been used to treat diseases such as cancer, chronic infection, and autoimmune disorders (5, 16). IL-4 signals through either a type I heterodimeric receptor comprised of IL-4 receptor-\(\alpha\) (IL-4Ra) and the \(\gamma_c\) subunit or a type II heterodimeric receptor comprised of IL-4Ra and IL-13Ra1 (3, 34). The crystal structure of the type I IL-4 cytokine–receptor complex extracellular domains has been determined, revealing that the membrane-proximal domains of the receptor ECDs form a “stem region” of intimate receptor–receptor contact (Fig. S1) (34). We targeted these stem regions to isolate monovalent antibody fragments that bridge the type I IL-4 receptor dimer by simultaneously binding to the membrane-proximal domains of IL-4Ra and \(\gamma_c\). Crystallographic analysis showed that our evolved stapler indeed binds an interface spanning the two receptor subunits. We then extended our selection strategy to evolve scFv's that stabilize the interface between another \(\gamma_c\) cytokine, interleukin-2 (IL-2), and one of its receptor subunits. We showed that these scFv's enhance IL-2–receptor interaction and potentiate cytokine signaling in the context of an activity-impaired mutant. With this proof-of-concept demonstration for evolution of customized scFv's that recognize composite surfaces, our strategy could, in principle, enable discovery of stapler antibodies that modulate the activity of cytokines and other classes of natural ligands for a variety of therapeutic indications.

Results

Devising an evolutionary scheme for selection of dimerizing stapler scFvs

To screen for IL-4 staplers, we selected a diverse (10\(^9\) clones) yeast-displayed nonimmune human scFv library (35) against the type I IL-4 cytokine–receptor ternary complex (i.e. cytokine bound to two receptor subunits) through iterative rounds of magnetic-activated cell sorting (MACS) (Fig. 1B). There were two critical considerations for the selection of stapler scFv's: 1) the stability of the cytokine–receptor complex selection reagent that served as the “molecular cast” of the signaling dimer and 2) the use of a multistep selection scheme to positively select against these stabilized complexes and negatively select against the individual subunits to enrich for scFv's that specifically bind to receptor dimers.

To ensure stability of the target complex throughout the IL-4 stapler selections, we substituted the cytokine with an engineered variant of IL-4 (denoted “Super-4”) that has 3700-fold higher affinity for \(\gamma_c\) (36) and used the stabilized Super-4/IL-4Ra/\(\gamma_c\) ternary complex as our positive selection reagent. For each round of selection, we carried out two steps of negative selection against 1) \(\gamma_c\) and 2) IL-4/IL-4Ra binary complex preceeding a positive selection step against the Super-4/IL-4Ra/\(\gamma_c\) target complex (Fig. S2). This sequence was iterated over six rounds of selection, decreasing only the concentration of the target complex to increase stringency.

Staplers selectively and specifically bind the cytokine–receptor ternary signaling complex

Following selections, the library converged on three scFv clones denoted A2 (henceforth referred to as “IL-4 stapler”), A8, and A11 (Fig. S3). The yeast-displayed IL-4 stapler, A8, and A11 scFv's exhibited robust binding to the Super-4 ternary complex but not to any of the individual components or binary complex combinations thereof (Fig. 1C and Fig. S4). These scFv's were also specific for the Super-4/IL-4Ra/\(\gamma_c\) ternary complex and showed no reactivity with the IL-13/IL-4Ra/IL-13Ra1 or IL-2/IL-2Ra/\(\gamma_c\) ternary complexes, indicating that receptor chain engagement occurred only in the context of the assembled IL-4Ra/\(\gamma_c\) heterodimer. On-yeast binding studies also revealed that IL-4 stapler bound weakly to the IL-4Ra chain and the Super-4/IL-4Ra/\(\gamma_c\) binary complex, but binding was substantially enhanced in the presence of the full Super-4/IL-4Ra/IL-13Ra1 and are thus highly specific for the IL-4Ra/\(\gamma_c\) type I IL-4 receptor heterodimer. This represents a major difference from endogenous IL-4, which cross-reacts with both type I and type II receptors and induces pleiotropic effects that have limited the utility of cytokine as a therapeutic to boost the type 2 helper T cell immune response (36).

The binding and specificity of recombinantly expressed IL-4 stapler scFv to the Super-4/IL-4Ra/\(\gamma_c\) target complex was eval-
Figure 1. Novel evolutionary selection strategy isolates antibody-based “staplers” that dimerize cytokine receptor chains. A, schematic contrasting receptor heterodimerization and activation induced by cytokine, antibody, or “stapler” scFv binding, respectively. B, layout and selection scheme for yeast display-based evolution of cytokine–receptor complex staplers. A yeast-displayed scFv library is evolved through iterative rounds of selection, each of which comprises negative clearance steps against the individual complex components and positive selection for binders to the fully assembled ternary complex. C, flow cytometry histograms depicting the binding of yeast-displayed IL-4 stapler scFv to the indicated cytokine–receptor complexes and individual components thereof. TC, ternary complex. D, kinetic SPR binding profiles for the interactions between the immobilized IL-4 stapler scFv and soluble Super-4/IL-4Rα/γc ternary complex components versus the fully assembled complex. All proteins were flowed at a concentration of 60 μM. E, surface plasmon resonance kinetic binding traces depicting the interaction between immobilized IL-4 stapler scFv and dilutions of the Super-4/IL-4Rα/γc ternary complex. The equilibrium dissociation constant (Kd) value was calculated by fitting the equilibrium titration curve to a logistic model via nonlinear regression. The top curve represents a concentration of 20 μM, and subsequent curves represent 3-fold serial dilutions.

Crystal structure of the ternary complex–bound IL-4 stapler reveals shared epitope between the IL-4Rα and γc subunits

To obtain structural evidence that the IL-4 stapler scFv recognizes a composite epitope formed by the conjunction of two receptor subunits (Fig. 1A), we restructured the stapler scFv as a Fab fragment and determined the crystal structure of the Super-4/IL-4Rα/γc ternary complex bound to the stapler Fab to 3.1 Å resolution (Fig. 2A, Fig. S6, and Table 1). As selections and binding studies were performed in the presence of cytokine, we expected that the stapler would engage the membrane-proximal "stem regions" of the receptor subunits, distal from the site of cytokine engagement. The Fab heavy-chain (HC)/light-chain (LC) heterodimer axis coincides almost perfectly with the IL-4Rα/γc dimer interface. We also found close agreement between the orientation of the IL-4Rα and γc subunits in the presence of the stapler compared with the natural ternary complex. The receptor chains in the stapler-bound Super-4/IL-4Rα/γc ternary complex align closely with their conformations in the native IL-4 type I ternary complex (PDB code 3BPL, RMSD = 0.506 Å for IL-4Rα and RMSD = 0.643 Å for γc). Furthermore, fixing the IL-4Rα1 subunit in both structures, the γc subunit is rotated by just 5.3° in the presence of the stapler. By comparison, a diabody that homodimerizes the erythropoietin receptor but elicits only weak agonist activity induces a 151° relative rotation in the receptor subunits (31).

The IL-4 stapler Fab interface with the receptor subunits is partitioned between the variable domains; whereas the IL-4Rα interface is dominated by contacts with the variable heavy (VH) chain, the γc interface principally comprises contacts with the variable light (VL) chain (Fig. 2B and Fig. S7). For both the VH and VL domains, all three complementarity-determining regions (CDRs) are implicated in receptor interactions. The more extensive Fab interface with IL-4Rα compared with γc rationalizes the weak affinity observed between IL-4 stapler and IL-4Rα alone (Fig. 2B and Fig. S7).
Isolating stapler scFvs that stabilize cytokine–receptor interactions

Given our success in engineering scFvs that recognize epitopes that span multiple cytokine receptor subunits, we attempted to extend the stapling concept to select for interface-bridging scFvs that stabilize interactions between cytokines and their cognate receptor subunits (Fig. 3A). In particular, we aimed to evolve a single-chain species that potentiates the interaction between the interleukin-2 (IL-2) cytokine and one of its receptor subunits. IL-2 signals through either a high-affinity ($K_D \approx 10 \text{ pm}$) heterotrimeric receptor comprised of the IL-2Rα, IL-2Rβ, and $\gamma_c$ chains or an intermediate-affinity ($K_D \approx 1 \text{ nM}$) heterodimeric receptor consisting of only the IL-2Rβ and $\gamma_c$ chains (Fig. S8) (38–40). The IL-2Rα chain is not implicated in signaling but rather calibrates IL-2 sensitivity through its differential expression levels on various cell types. IL-2Rα is highly expressed on regulatory T (TReg) cells but virtually absent from naive CD8+ T and natural killer (NK) cells; hence, TReg cells are 100-fold more responsive to IL-2 than these immune effector cell types (38, 41). A variant of IL-2 with 200-fold enhanced affinity for the IL-2Rβ chain (denoted “Super-2”) was previously engineered to sensitize IL-2Rα–deficient cells to IL-2. Super-2 promoted expansion of cytotoxic T cells to effectively inhibit tumor growth in mice (42). We hypothesized that an scFv stapler that stabilized the IL-2/IL-2Rβ interaction would recapitulate the behavior of Super-2. Moreover, therapeutic use of an exogenous antibody offers several advantages over administration of a cytokine mutant, such as improved serum half-life (23, 24), controllable dose-dependent activation of IL-2–responsive cells, and the ability to selectively modulate rather than compete with endogenous IL-2.

Recently, Kuruganti et al. (32) selected antibody fragments that stabilize the IFN/interferon receptor 2 (IFNAR2) binary complex to potentiate IFN signaling. Following a selection scheme similar to those used for IL-4 stapler discovery (Fig. 3B and Fig. S9), we evolved an scFv that uniquely recognizes the IL-2/IL-2Rβ binary complex but not either individual component thereof. We performed iterative rounds of selection against the aforementioned scFv library (35), clearing independently against 1) Super-2 and 2) IL-2Rβ prior to positively selecting for binders to the Super-2/IL-2Rβ complex, again capitalizing on the enhanced affinity of a mutant cytokine (Super-2) to stabilize the target complex (Fig. 3B). Selections converged on a single scFv clone (denoted the IL-2 binary complex stapler, or “IL-2B stapler”) that was then affinity-matured through selection of a site-specific mutagenic library of the VH and VL CDR3 regions (Fig. S10).

Both the parent IL-2B stapler and the affinity-matured variant thereof (denoted the “amIL-2B stapler”) bound the IL-2/IL-2Rβ interaction with high affinity (35), recapitulating the behavior of Super-2. The IL-2B stapler was further covalently linked to a second antibody (denoted the “Duo-2 stapler”) to create a heterodimeric species capable of stabilizing both the IL-2/IL-2Rβ and IL-4/IL-4Rβ interfaces simultaneously (Fig. 3C). This construct was effective in promoting the expansion of cytotoxic T cells in vitro and in vivo (Fig. 4).

Figure 2. Stapler recognizes a composite epitope between two receptor subunits to bridge the dimer interface. A, orthosteric views of the crystallographic structure of the IL-4 stapler Fab fragment bound to the Super-4/IL-4Rα/γc ternary complex. B, enlarged views of the IL-4 stapler interfaces with the IL-4Rα and γc subunits. At the left, IL-4 stapler-binding sites on IL-4Rα and γc are depicted in gray, with interacting residues in the CDRs of the VH (magenta) and VL (olive) domains of the IL-4 stapler Fab shown as sticks. At the right, the CDRs on VH (magenta) and VL (olive) of the IL-4 stapler Fab are shaded.
Editors’ Pick: Antibodies that span protein dimer interfaces

Table 1
Crystallographic statistics for Super-4/IL-4Rα/γc/IL-4 stapler Fab complex

| Parameters                        | Values                  |
|-----------------------------------|-------------------------|
| Data collection                   | 0.9999                  |
| Wavelength                        |                         |
| Resolution range                  | 63.1–3.10 (3.22–3.10)   |
| Space group                       | F 41 3 2                |
| Unit cell                         | 328.1, 328.1, 328.1, 90, 90, 90 |
| Total reflections                 | 493,043 (45,665)        |
| Unique reflections                | 27,836 (1462)           |
| Completeness (%)                  | 95.0 (53.3)             |
| Redundancy                        | 17.7 (16.8)             |
| Mean I/0(1)                       | 14.9 (0.92)             |
| R-merge                           | 0.275 (4.18)            |
| CC1/2                             | 0.997 (0.343)           |

| Refinement statistics             |                         |
|-----------------------------------|-------------------------|
| Reflections used in refinement    | 26,537 (1462)           |
| Reflections used for Rfree        | 1327 (74)               |
| Rwork                             | 0.199 (0.316)           |
| Rfree                             | 0.256 (0.4118)          |
| Number of non-hydrogen atoms      | 7209                    |
| Macromolecules                    | 7091                    |
| Ligands                           | 98                      |
| Solvent                           | 20                      |
| Protein residues                  | 922                     |
| RMSD (bonds)                      | 0.003                   |
| RMSD (angles)                     | 0.57                    |
| Ramachandran favored (outliers)   | 95.0 (0)                |
| Average B-factor                  | 77.1                    |
| Macromolecules                    | 76.6                    |
| Ligands                           | 112                     |
| Solvent                           | 77.1                    |
| Number of TLS groups              | 22                      |

* Values in parentheses are for the highest-resolution shell.

2Rβ binary complex, but not the cytokine or receptor independently (Fig. 3C). IL-2B staplers also bound the IL-2/I-L2Rβ/γc ternary complex, which is critical for signaling activity. The IL-2B stapler bound the stabilized Super-2/I-L2Rβ binary complex with similar affinity (Kd = 210 nM) to the IL-2/I-L2Rβ interaction (42), and the amIL-2B/CAP stapler exhibited a 14-fold higher affinity for the binary complex (Kd = 15 nM; Fig. 3D and Fig. S1A). Both IL-2B stapler scFvs enhanced the IL-2/I-L2Rβ interaction ~15-fold, although this improvement was less dramatic than the 70-fold enhancement observed with the Super-2 cytokine mutant (Fig. 4A). Due to this more modest affinity improvement and the high potency of WT IL-2 signaling, IL-2B staplers did not potentiate cytokine activity on IL-2–responsive cells, as measured by phosphorylation of the downstream transcription factor signal transducer and activator of transcription 5 (STAT5, Fig. S1B). We speculated that the effect of the staplers would be more pronounced in the context of an impaired IL-2 variant reported by Shanafelt et al. (43), which exhibits weakened activity due to its reduced affinity for IL-2Rβ. This variant (which we denote “IL-2”) has been shown to selectively bias cytokine activity toward particular immune cell subsets based on their IL-2 receptor expression profiles (43). IL-2B stapler and amIL-2B stapler enhanced IL-2–induced STAT5 activity 9- and 23-fold, respectively (Fig. 4B), establishing the potential utility of binary complex stapler scFvs to selectively potentiate immune cells for such applications as T cell activation in cancer immunotherapy (38, 44). Taken together, our biophysical, structural, and functional characterization of staplers demonstrates that through stringent selection against stabilized cytokine–receptor complexes, we have engineered antibody fragments that specifically recognize and modulate the stability of protein interfaces.

Discussion

The ability to isolate scFvs that use a single binding site to bridge bimolecular interactions from a naive antibody fragment library presents an exciting opportunity in antibody engineering. A naive scFv library of diversity 109, which was derived from pooled spleen and lymph nodes of 58 human donors (35), yielded three unique IL-4 ternary complex stapler clones and one unique IL-2 binary complex stapler clone, and it will be interesting to explore the frequency of stapler antibodies in both natural and synthetic libraries going forward. Moreover, our IL-2 cytokine–receptor stapler demonstrates the unexpected ability to stabilize a protein interface. Previous work has shown that catalytic antibodies can be elicited by raising antibodies that target the transition state of reactions (45, 46). Our biophysical and functional data suggest that staplers instead act through stabilization of the receptor heterodimer to bias the equilibrium toward the dimeric over the monomeric receptor state.

Whereas our study is limited to a proof of concept and in vitro studies, a potential advantage of the stapler platform is that it allows for modulation of the heterodimerization properties of membrane-bound receptors through recognition of specific receptor complexes. Regulating heterodimer distribution on cells has value from both a research discovery and a therapeutically perspective (36). Altered dimerization patterns could have profound functional implications, particularly for cytokine systems such as IL-4, which signal through formation of either a type I or type II receptor complex to evoke distinct immune behavior (3, 34). In addition, the specificity of staplers makes a compelling case for their use in targeted activation of transplanted cells. Previous efforts have been employed to engineer natural cytokines (22, 36, 42, 47), to design synthetic cytokine fusions (48), or to computationally engineer de novo cytokine mimetics (49) to redirect cytokine activities to specific cell subsets. The stapler strategy allows for an additional layer of control through administration of a molecule that is noncompetitive with natural cytokine activity.

The engineering opportunities available to the scFv scaffold enable possibilities for molecular therapeutic design. Stapler scFvs can be conjugated to scFvs that engage cell surface markers to form bispecific antibodies that selectively modulate dimerization behavior on particular immune cell subsets for targeted disease therapy. Efforts to achieve cell subset-specific signaling by directly fusing cytokines to surface marker–directed antibodies have been unsuccessful, as the high potency of cytokines nullifies the effect of targeting antibodies, resulting in nonspecific activation of many immune cell subtypes (50–52). In contrast, the affinities of the stapler scFv and cell surface marker–targeted scFvs can be easily evolved through manipulation of the CDR loop regions (as was done in our binary stapler affinity maturation) to finely control their relative potencies and thereby optimize functional selectivity. Furthermore, discovery and
structural characterization of the IL-4 stapler paves the way for engineering staplers that modulate other γc-engaging cytokines (including IL-7, IL-9, and IL-21) (16). In summary, we have established a new evolutionary approach to isolate a novel class of stapler scFvs. These engineered molecules offer insight into the biophysical requirements for dimerization and signal activation, and they provide a structural framework for the development of targeted immunotherapeutics.
Experimental procedures

Protein expression and purification

Human IL-2 and variants thereof (amino acids 1–133), the IL-2Rβ ectodomain (amino acids 1–214), γc (amino acids 34–232), IL-2RA (amino acids 1–217), IL-15 (amino acids 1–114), and IL-15Rα (amino acids 1–67) were expressed and purified using a baculovirus expression system as described (39). Super-2 refers to the previously reported IL-2 variant purified using a baculovirus expression system as described (34). The sequence for the ectodomain (amino acids 1–310) were expressed and purified using a baculovirus expression system (34). The sequence for the Super-4 variant of IL-4 was provided previously (36). scFv clones isolated from selection were expressed and purified in the baculovirus system via transfer of their variable regions into the pAcGP67A vector containing 3C protease-cleavable basic and acidic leucine zippers. Fab expression, the identified VH followed by the human IgG1 constant heavy 1 (CH1) domain and hinge region and the identified VL domain followed by the human κ constant light (CL) domain were separately cloned into the pAcGP67A vector (BD Biosciences) with an N-terminal gp67 signal peptide and a C-terminal hexahistidine tag. scFvs were eluted in 10 mM HEPES, pH 7.3, 200 mM imidazole in the presence of 15% glycerol and 500 mM NaCl and then exchanged into standard HEPES-buffered saline (10 mM HEPES, pH 7.3, 150 mM NaCl). The VH and VL chains of stapler scFvs were delineated using the International Immunogenetics Information System (IMGT) V-QUEST tool (53, 54). For IL-4 stapler Fab expression, the identified VH followed by the human IgG1 constant heavy 1 (CH1) domain and hinge region and the identified VL domain followed by the human κ constant light (CL) domain were separately cloned into the pAcGP67A vector containing 3C protease-cleavable basic and acidic leucine zipers, respectively, for high-fidelity Fab chain pairing (55, 56). The resulting Fab HC and LC constructs were transfected independently, and their corresponding viruses were co-titrated to determine optimal infection ratios for equivalent expression of the two chains. The secreted IL-4 stapler Fab was treated with 3C protease to remove the leucine zipers prior to size-exclusion chromatographic purification.

For biotinylated protein expression, Super-4, IL-4RA, IL-13RA1, or γc with a C-terminal biotin acceptor peptide, LNDIFEAQKIEWHE, were co-expressed with the BirA ligase enzyme in the presence of excess biotin (100 μM), or the purified proteins were biotinylated in vitro using the soluble BirA ligase enzyme in 0.5 mM Bicine, pH 8.3, 100 mM ATP, 100 mM magnesium acetate, and 500 mM biotin (Sigma). For surface plasmon resonance (SPR) studies, purified stapler scFvs were biotinylated using the EZ-Link Sulfo-NHS-LC-biotinylation kit (Pierce) according to the manufacturer’s protocol. All proteins contained C-terminal hexahistidine tags and were isolated by nickel chromatography. They were then further purified to >98% homogeneity by size-exclusion chromatography on a Superdex 200 column (GE Healthcare), equilibrated in 10 mM HEPES (pH 7.3) and 150 mM NaCl.

Tissue culture

YT-1 human NK cells (57) were cultured in RPMI complete medium (RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, minimum nonessential amino acids, sodium pyruvate, 25 mM HEPES, and penicillin-streptomycin (Gibco)). The Ramos human B lymphocyte cell line (58) was grown in RPMI containing 10% FBS, l-glutamine (2 mM), and penicillin/streptomycin (Gibco). Prior to stimulation, Ramos cells were cultured overnight in modified growth medium containing only 2% FBS (“starved”).

Yeast library selection of stapler scFvs

General yeast display methodologies were modified from protocols described previously (42, 59, 60). The previously described human nonimmune scFv yeast library (35) was kindly provided by K. Dane Wittrup and was used to isolate the IL-4 and IL-2 stapler scFvs. For all selection schemes, the first round of sorting was performed with 1 × 10^10 cells from the naive yeast library to achieve 10-fold coverage of the number of transformants, and subsequent rounds used 1 × 10^8 yeast cells. Tetramers were formed by incubating a 4:1 ratio of biotinylated protein to Alexa 647–conjugated streptavidin (SA-647) for 15 min on ice. Magnetic bead selections were performed using LS MACS separation columns (Miltenyi Biotec) according to the manufacturer’s protocol. The naive scFv library and each iterative panel of selected clones were grown fresh overnight at 30 °C in SDCAA liquid medium (pH 4.5), followed by induction in SGCAM liquid medium (pH 4.5) for 2 days at 20 °C. In the first round of selection for the IL-4 ternary complex staplers, yeast-displayed scFvs were incubated with biotinylated γc bound to magnetic beads coated with SA (400 nM γc in 250 μl of SA-coated beads) (Miltenyi Biotec) in the presence of 1 μM nonbiotinylated IL-4Rα and Super-4, an IL-4 mutant that exhibits 3700-fold higher affinity for γc than WT IL-4 (36), in PBE solution (PBS, pH 7.2, 1% BSA, and 1 mM EDTA) for 2 h at 4 °C. In each subsequent round of selection, two steps of negative selection and one step of positive selection were carried out in sequence. In a first step, yeast were stained with biotinylated γc that had been tetramerized via incubation with SA-647 (500 nM) for 1 h in PBE at 4 °C and negatively selected by incubating the yeast with 50 μl of anti-Alexa 647 microbeads (Miltenyi Biotec) in PBE for 15 min at 4 °C. In a second step, the flow-through yeast from the first step were incubated with SA-647–tetramerized biotinylated IL-4Rα (500 nM) and 1 μM of nonbiotinylated Super-4 for 1 h in PBE at 4 °C. The yeast were then negatively selected via incubation with 50 μl of anti-Alexa 647 microbeads (Miltenyi Biotec) in PBE for 15 min at 4 °C. In a final step, the flow-through yeast from the second step were incubated with SA-647–tetramerized biotinylated γc (500 nM) in the presence of 1 μM nonbiotinylated IL-4Rα and Super-4 for 1 h in PBE at 4 °C and positively selected by incubation with 50 μl of anti-Alexa 647 microbeads (Miltenyi Biotec) in PBE for 15 min at 4 °C. This workflow was repeated over six rounds of selection in which only the concentration of the positive selection reagents was decreased to isolate scFvs specifically binding the IL-4 ternary complex with high affinity. Three scFv clones, denoted A2 (the “IL-4 stapler”), A8, and A11, were isolated, and all exhibited specific binding for the IL-4 ternary complex and no binding for the individual components of that complex (i.e. Super-4, IL-4Rα, or γc). The complementarity-determining
region 3 (CDR3) domain sequences of isolated IL-4 staplers are provided in Fig. S3.

**IL-2 binary complex stapler scFv selections and affinity maturation**

In the first round of selection for an IL-2 binary complex stapler, the naive library of yeast-displayed scFvs was stained with biotinylated IL-2Rβ bound to SA-coated magnetic beads (400 nM IL-2Rβ in 250 μL of SA-coated beads) (Miltenyi Biotech) in the presence of 1 μM nonbiotinylated Super-2, a variant of IL-2 with 200-fold greater affinity for the IL-2Rβ receptor subunit (42), for 2 h at 4 °C. In each subsequent round of selection, two negative selection steps and one positive selection step were conducted sequentially. In a first step, yeast were stained with SA-647–tetramerized biotinylated Super-2 (500 nM) for 1 h in PBE at 4 °C. Negative selections were performed by incubating the yeast with 50 μL of anti-Alexa 647 microbeads (Miltenyi Biotech) in PBE for 15 min at 4 °C. In a second step, the flow-through yeast from the first step were incubated with SA-647–tetramerized biotinylated IL-2Rβ (500 nM) for 1 h in PBE at 4 °C. Negative selections were again performed by incubating the yeast with 50 μL of anti-Alexa 647 microbeads (Miltenyi Biotech) in PBE for 15 min at 4 °C. In a final step, the flow-through yeast from the second step were incubated with SA-647–tetramerized biotinylated IL-2Rβ (500 nM) and 1 μM nonbiotinylated Super-2 for 1 h at 4 °C. Positive selections were conducted by incubating the yeast with 50 μL of anti-Alexa 647 microbeads (Miltenyi Biotech) in PBE for 15 min at 4 °C. Iterations of this workflow were repeated over six rounds of selection in which the only concentrations of the positive selection reagents were decreased to isolate scFv clones specifically binding with high affinity to the IL-2 binary complex. Selections converged on a single clone, the IL-2 binary complex stapler (“IL-2B stapler”).

The site-directed mutagenic library used for affinity maturation of IL-2B stapler was constructed via assembly PCR of 16 primers spanning the Vδ and Vγ chains of the scFv. The following degenerate codons were used: Ala-104, RYK; Val-105, RYK; Ser-106, DMY; Gly-107, RBY; Thr-108, DMY; Phe-109, HWY; Tyr-236, WWY; Asp-237, VAK; Asp-238, VAK; Asn-239, VAK; Ser-106, DMY; Gly-107, RBY; Thr-108, DMY; Phe-109, HWY; Tyr-236, WWY; Asp-237, VAK; Asp-238, VAK; Asn-239, VAK; Tyr-240, WWY. The assembly PCR was carried out using Pfu Ultra DNA polymerase (Strategene), and the product was further amplified using primers containing sequence homology to pCT302 for recombination inside the yeast. Insert DNA was combined with linearized vector backbone and electroporated into EBY100 yeast as described previously. Electroporation yielded a library of 1 × 10^8 transformants. Selections were performed as detailed for the IL-2 binary complex stapler, but with 10-fold reduced concentrations of positive selection reagents to heighten stringency. Selections converged on a single clone, the affinity-matured IL-2 binary complex stapler (amIL-2B stapler). The CDR3 domain sequences of the IL-2 binary complex stapler (IL-2B stapler) and the affinity-matured IL-2 binary stapler (amIL-2B stapler) are provided in Fig. S9.

**Yeast surface stapler scFv-binding studies**

Yeast displaying stapler scFvs (2 × 10^3/well) were plated in a 96-well plate and incubated in PBE buffer containing a 1 μM concentration of the indicated biotinylated IL-4 or IL-2 complex components for 2 h at room temperature. Cells were then washed and incubated for 20 min at 4 °C with 50 nM SA-647 diluted in PBE. After a final wash, cells were analyzed for binding using an Accuri C6 flow cytometer (BD Biosciences). Representative plots from one of three independent experiments are presented. Cytometry data were analyzed using FlowJo software (Tree Star, Inc.).

**Surface plasmon resonance binding measurements**

Binding interactions were characterized via SPR studies using Biacore SA sensor chips (GE Healthcare) on a Biacore T100 instrument at 25 °C. All recombinantly produced proteins were purified via size-exclusion chromatography on an FPLC instrument and filtered through a 0.22-μm centrifugal column prior to SPR analysis. Biotinylated scFv stapler clones were immobilized to the chip surface at low density (RU_max < 200 response units), and measurements were performed at a flow rate of 30 ml/min to minimize mass transport contributions and prevent rebinding of the analyte. Dilutions of the analytes (IL-4 cytokine–receptor complex components) were exposed to the surface channels for 60 s, and dissociation was measured for 180–300 s. For the case of protein complexes, complex components were incubated for 30 min at room temperature prior to SPR analysis. An irrelevant scFv was used in the reference channel to subtract nonspecific binding from the measurements. Experiments were performed in HBS-P+ buffer (GE Healthcare) supplemented with 0.2% BSA. Data were visualized and processed using the Biacore T100 evaluation software (GE Healthcare). Equilibrium titration curves were fitted to a logistic model via nonlinear regression, and equilibrium dissociation constant (K_D) values were determined using GraphPad Prism analysis software assuming 1:1 binding interactions.

**Crystallization and data collection**

For crystallographic analysis, the Super-4, IL-4Ro, and γ_c viruses were co-expressed in insect cells in the presence of 5 μM kifunensine, added to culture at the time of infection. The resulting kifunensine-sensitized Super-4 ternary complex was purified via nickel chromatography and then treated overnight at 4 °C with 1:100 (w/w) endoglycosidases F1 and H to remove N-linked glycans and with 1:100 (w/w) carboxypeptidases A and B (Sigma) to remove C-terminal hexahistidine tags. The complex was then purified by size-exclusion chromatography. Separately, the IL-4 stapler Fab was secreted in insect cells via co-infection of heavy- and light-chain viruses and purified via nickel chromatography. The assembled Fab was then treated overnight at 4 °C with 1:1000 (w/w) 3C protease to remove acidic and basic leucine zippers and hexahistidine tags and purified by size-exclusion chromatography. Stoichiometrically equivalent amounts of the purified Super-4/IL-4Ro/γ_c ternary complex and the IL-4 stapler Fab were co-incubated for 4 h at 4 °C to allow for complex formation, and the resulting Fab-bound cytokine–receptor complex was purified by co-elution over a Superdex-200 size-exclusion chromatography column and concentrated to >10 mg/mL. Super-4/IL-4Ro/γ_c/IL-4 stapler Fab crystals were grown in sitting drops at 22 °C in 22.5% PurePEG (Microlytic), 0.1 M sodium citrate, pH 5.5, and 0.6 M ammonium nitrate. Crystals were cryoprotected with the addition of 30% ethylene glycol (Sigma) and flash-cooled in liquid nitrogen. A 3.1 Å data set was collected at beamline 8.2.1 at EMBL-DE.

**EDITORS’ PICK: Antibodies that span protein dimer interfaces**

For crystallographic analysis, the Super-4, IL-4Ro, and γ_c viruses were co-expressed in insect cells in the presence of 5 μM kifunensine, added to culture at the time of infection. The resulting kifunensine-sensitized Super-4 ternary complex was purified via nickel chromatography and then treated overnight at 4 °C with 1:100 (w/w) endoglycosidases F1 and H to remove N-linked glycans and with 1:100 (w/w) carboxypeptidases A and B (Sigma) to remove C-terminal hexahistidine tags. The complex was then purified by size-exclusion chromatography. Separately, the IL-4 stapler Fab was secreted in insect cells via co-infection of heavy- and light-chain viruses and purified via nickel chromatography. The assembled Fab was then treated overnight at 4 °C with 1:1000 (w/w) 3C protease to remove acidic and basic leucine zippers and hexahistidine tags and purified by size-exclusion chromatography. Stoichiometrically equivalent amounts of the purified Super-4/IL-4Ro/γ_c ternary complex and the IL-4 stapler Fab were co-incubated for 4 h at 4 °C to allow for complex formation, and the resulting Fab-bound cytokine–receptor complex was purified by co-elution over a Superdex-200 size-exclusion chromatography column and concentrated to >10 mg/mL. Super-4/IL-4Ro/γ_c/IL-4 stapler Fab crystals were grown in sitting drops at 22 °C in 22.5% PurePEG (Microlytic), 0.1 M sodium citrate, pH 5.5, and 0.6 M ammonium nitrate. Crystals were cryoprotected with the addition of 30% ethylene glycol (Sigma) and flash-cooled in liquid nitrogen. A 3.1 Å data set was collected at beamline 8.2.1 at EMBL-DE.
the Advanced Light Source. Diffraction data were processed using HKL2000. Crystallographic data collection and refinement statistics are reported in Table 1.

**Structure determination and refinement**

The Super-4/IL-4Ra/γc/IL-4 stapler Fab complex structure was solved by molecular replacement using PHASER (61). The IL-4 ternary complex structure reported previously (PDB code 3BPL) (34) was used to model Super-4, IL-4Ra, and γc, and models of the IL-4 stapler Fab heavy and light chains were obtained from the previously solved structure of a human Fab (PDB code 3SOB) (62). Iterative model rebuilding and refinement were performed using the Phenix software (63) and COOT (Crystallographic Object-Oriented Toolkit) (64). For initial refinement, rigid body, coordinate, and real-space refinement were used with individual atomic displacement parameter refinement. Translation, libration, and screw-rotation refinement was added in later iterations. Ramachandran and rotamer analysis were performed using MolProbity (65).

Atomic interactions were identified using the PISA (protein interfaces, surfaces, and assemblies) service at the European Bioinformatics Institute (66). Structural figures were created using PyMOL (The PyMOL Molecular Graphics System, version 2.0 Schrödinger, LLC). Crystallographic software was installed and configured by SBGrid (67).

**YT-1 signal response experiments and phospho-flow cytometric analysis**

Approximately 3 × 10^5 YT-1 cells were plated in each well of a 96-well plate, washed with FACS buffer, and resuspended in FACS buffer containing serial dilutions of stapling scFvs or cytokines (used as positive controls for signal activation). Cells were stimulated for 20 min at 37 °C and immediately fixed by the addition of formaldehyde to 1.5% followed by incubation for 10 min at room temperature. Cells were then permeabilized with 100% ice-cold methanol for 30 min at 4 °C. The fixed and permeabilized cells were washed twice with FACS buffer and incubated with Alexa 488–conjugated anti-STAT5 pTyr-694 antibody (BD Biosciences) diluted in FACS buffer for 2 h at room temperature. Cells were then washed twice in FACS buffer, and mean fluorescence intensity was quantified on an Accuri C6 flow cytometer. Dose-response curves were fitted to a logistic model, and half-maximal effective concentrations (EC_{50} values) were computed in the GraphPad Prism data analysis software after subtraction of the mean fluorescence intensity of unstimulated cells and normalization to the maximum signal intensity induced by cytokine stimulation.

**Acknowledgments**—We thank members of the Garcia laboratory for helpful advice and discussions and A. Velasco, D. Waghray, and S. Fischer for technical assistance. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the United States Department of Energy under Contract DE-AC02-05CH11231.

**References**

1. Ullrich, A., and Schlessinger, J. (1990) Signal transduction by receptors with tyrosine kinase activity. *Cell* 61, 203–212 CrossRef Medline
2. Klemm, J. D., Schreiber, S. L., and Crabtree, G. R. (1998) Dimerization as a regulatory mechanism in signal transduction. *Annu. Rev. Immunol.* 16, 569–592 CrossRef Medline
3. Wang, X., Lupardus, P., Laporte, S. L., and Garcia, K. C. (2009) Structural biology of shared cytokine receptors. *Annu. Rev. Immunol.* 27, 29–60 CrossRef Medline
4. Bazan, J. F. (1989) A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor B-chain. *Biochem. Biophys. Res. Commun.* 164, 788–795 CrossRef Medline
5. Rochman, Y., Spolski, R., and Leonard, W. J. (2009) New insights into the regulation of T cells by γc family cytokines. *Nat. Rev. Immunol.* 9, 480–490 CrossRef Medline
6. Cunningham, B. C., Ulltsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. *Science* 254, 821–825 CrossRef Medline
7. Watowich, S. S., Hilton, D. J., and Lodish, H. F. (1994) Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. *Mol. Cell Biol.* 14, 3535–3549 CrossRef Medline
8. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., and Silvennoinen, O. (1995) Signaling through the hematopoietic cytokine receptor. *Annu. Rev. Immunol.* 13, 369–398 CrossRef Medline
9. Syed, R. S., Reid, S. W., Li, C., Cheetham, J. C., Aoki, K. H., Lu, B., Zhan, H., Osslund, T. D., Chirino, A. J., Zhang, J., Finer-Moore, J., Elliott, S., Stitney, K., Katz, B. A., Matthews, D. J., Wendoloski, J. J., Egrie, J., and Stroud, R. M. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. *Nature* 395, 511–516 CrossRef Medline
10. Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K., and Wilson, I. A. (1999) Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. *Science* 283, 987–990 CrossRef Medline
11. Constantinescu, S. N., Keren, T., Socolovsky, M., Nam, H., Henis, Y. I., and Lodish, H. F. (2001) Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. *Proc. Natl. Acad. Sci. U.S.A.* 98, 4379–4384 CrossRef Medline
12. Delgoffe, G. M., Murray, P. J., and Vignali, D. A. A. (2011) Interpreting mixed signals: the cell’s cytokine conundrum. *Curr. Opin. Immunol.* 23, 632–638 CrossRef Medline
13. Levy, D. E., and Darnell, J. E. (2002) Stat's: transcriptional control and biological impact. *Nat. Rev. Mol. Cell Biol.* 3, 651–662 CrossRef Medline
14. Murray, P. J. (2007) The Jak-STAT signaling pathway: input and output integration. *J. Immunol.* 178, 2623–2629 CrossRef Medline
15. O’Shea, I. J., and Plenge, R. (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. *Immunity* 36, 542–550 CrossRef Medline
16. Overwijk, W. W., and Schluns, K. S. (2009) Functions of γc cytokines in immune homeostasis: current and potential clinical applications. *Clin. Immunol.* 132, 153–165 CrossRef Medline
17. Pellegrini, M., Mak, T. W., and Ohashi, P. S. (2010) Fighting cancers from within: augmenting tumor immunity with cytokine therapy. *Trends Pharmacol. Sci.* 31, 356–363 CrossRef Medline
18. Donohue, J. H., and Rosenberg, S. A. (1983) The fate of interleukin-2 after in vivo administration. *J. Immunol.* 130, 2203–2208 CrossRef Medline
22. Spangler, J. B., Moraga, I., Mendoza, J. L., and Garcia, K. C. (2015) Insights
23. Kuruganti, S., Miersch, S., Deshpande, A., Speir, J. A., Harris, B. D.,
24. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh,
25. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh,
26. Müller-Newen, G., Küster, A., Wijdenes, J., Schaper, F., and Heinrich, P. C.
27. Kai, M., Motoki, K., Yoshida, H., Emuta, C., Chisaka, Y., Tsuruhata, K.,
28. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh,
29. Nakano, K., Kojima, T., Kasutani, K., Senoh, C., Natori, O., Ishii, S.,
30. Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D.,
31. Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C. P., Hong,
32. J. Biol. Chem. 275, 4579–4586 CrossRef Medline
33. Proc. Natl. Acad. Sci. U.S.A. 26, 209–211 CrossRef Medline
34. Proc. Natl. Acad. Sci. U.S.A. 109, 15728–15733 CrossRef Medline
35. Feldhaus, M. J., Siegel, R. W., Opresko, L. K., Coleman, J. R., Feldhaus,
36. Nature 484, 529–533 CrossRef Medline
37. Hage, T., Sebald, W., and Reinemer, P. (1999) Crystal structure of the
38. Nature Signal. 7, ra50 CrossRef Medline
39. Shanafeld, A. B., Lin, Y., Shanafeld, M. C., Forte, C. P., Dubois-Sullivan,
40. villa et al. (2019) Discovery of the next generation of IL-2 and IL-15.
41. Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida,
42. Nature 565, 186–191 CrossRef Medline
43. Shusterian, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D.,
44. Nature 453–479 CrossRef Medline
45. Pollack, S. J., Jacobs, I. W., and Schultz, P. G. (1986) Selective chemical
catalysis by an antibody. Science 234, 1570–1573 CrossRef Medline
46. Tramontano, A., Janda, K. D., and Lerner, R. A. (1986) Catalytic antibod-
47. Science 234, 1566–1570 CrossRef Medline
48. Tramontano, A., Janda, K. D., and Lerner, R. A. (1986) Catalytic antibod-
49. Nature 453, 13876–13886 CrossRef Medline
50. Johnson, H. B., Moraga, I., Mendoza, J. L., Kakinuma, T., Mori, T.,
51. and immunotherapy. Nature 512, 242–247 CrossRef Medline
52. Zhang, H., Wilson, I. A., and Lerner, R. A. (2012) Selection of antibodies
that regulate phenotype from intracellular combinatorial antibody libraries.
Proc. Natl. Acad. Sci. U.S.A. 109, 15728–15733 CrossRef Medline
53. Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C. P., Hong,
54. Nature 209–211 CrossRef Medline
55. Nature 271, 447–461 CrossRef Medline
56. Adams, R., Burnley, R. J., Valenzano, C. R., Quereshi, O., Doyle, C., Lumb,
57. and immunotherapy. Nature 496, 4975–4980 CrossRef Medline
58. Széczényi, A., Gerlach, W., Katchova, M., Behrendt, J., Steinhilber, K.,
59. Nature 28, 4969–4975 CrossRef Medline
60. Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G.,
61. 232–332 CrossRef Medline
62. Science 282, 777–780 CrossRef Medline
63. Proc. Natl. Acad. Sci. U.S.A. 112, 3320–3325 CrossRef Medline
64. Cell 132, 259–272 CrossRef Medline
(2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 CrossRef Medline

53. Brochet, X., Lefranc, M.-P., and Giudicelli, V. (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503–W508 CrossRef Medline

54. Giudicelli, V., Brochet, X., and Lefranc, M.-P. (2011) IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc. 2011, 695–715 CrossRef Medline

55. Bankovich, A. J., Raunser, S., Juo, Z. S., Walz, T., Davis, M. M., and Garcia, K. C. (2007) Structural insight into pre-B cell receptor function. Science 316, 291–294 CrossRef Medline

56. Chang, H. C., Bao, Z., Yao, Y., Tse, A. G., Goyarts, E. C., Madsen, M., Kawasaki, E., Brauer, P. P., Sacchettini, J. C., and Nathenson, S. G. (1994) A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl. Acad. Sci. U.S.A. 91, 11408–11412 CrossRef Medline

57. Yodoi, J., Teshigawara, K., Nikaido, T., Fukui, K., Noma, T., Honjo, T., Takigawa, M., Sasaki, M., Minato, N., and Tsu, O. W., Huang, O. W., Estevez, A., Zilberley, L, Rouge, L., Chiu, C., Wu, Y., Costa, M., Hannoush, R. N., Franke, Y., and Cochran, A. G. (2011) Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure 19, 1433–1442 CrossRef Medline

58. Klein, G., Giovanella, B., Westman, A., Stehlin, J. S., and Mumford, D. (1975) An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 5, 319–334 CrossRef Medline

59. Boder, E. T., and Wittrup, K. D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557 CrossRef Medline

60. Chao, G., Lau, W. L., Hackel, B. J., Sazinsky, S. L., Lippow, S. M., and Wittrup, K. D. (2006) Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755–768 CrossRef Medline

61. McCoy, A. J., Grosse-Kunstleve, R. W., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 CrossRef Medline

62. Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., Huang, O. W., Estey, E., Zilberley, L., Rouge, L., Chiu, C., Wu, Y., Costa, M., Hannoush, R. N., Franke, Y., and Cochran, A. G. (2011) Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure 19, 1433–1442 CrossRef Medline

63. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Read, R. I., Shah, T. S., Sauter, N. K., and Terwilliger, T. C. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948–1954 CrossRef Medline

64. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 CrossRef Medline

65. Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., 3rd, Snoeyink, J., Richardson, J. S., and Richardson, D. C. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375–W383 CrossRef Medline

66. Kressin, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 CrossRef Medline

67. Morin, A., Eisenbraun, B., Key, S., Sanschagrin, P. C., Timony, M. A., Otviano, M., and Sliz, P. (2013) Collaboration gets the most out of software. eLife 2, e01456 CrossRef Medline